Dilated cardiomyopathy (DCM) is a group of diverse myocardial disorders characterized
by left ventricular (LV) or biventricular dilation, normal wall thickness, and global
systolic dysfunction without associated pressure/volume overload, coronary artery
disease, or valvular heart disease.
1
The prevalence of DCM in the general population remains undefined, with early estimates
at 1:2500 individuals; recent estimates are higher at >1:250 individuals.
- Pinto Y.M.
- Elliott P.M.
- Arbustini E.
- et al.
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated
cardiomyopathy, and its implications for clinical practice: a position statement of
the ESC working group on myocardial and pericardial diseases.
Eur Heart J. 2016; 37: 1850-1858
2
The etiology of DCM can be genetic or nongenetic, with the latter including myocardial
damage via infection/toxins, endocrine/metabolic abnormalities, inflammation, and
pregnancy.
1
,- Pinto Y.M.
- Elliott P.M.
- Arbustini E.
- et al.
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated
cardiomyopathy, and its implications for clinical practice: a position statement of
the ESC working group on myocardial and pericardial diseases.
Eur Heart J. 2016; 37: 1850-1858
2
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.Eur Heart J. 2016; 37: 1850-1858
- Cardiomyopathies and genetic testing in heart failure: role in defining phenotype-targeted approaches and management.Can J Cardiol. 2021; 37: 547-559
- Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals.Genet Med. 2010; 12: 655-667
- An evidence-based assessment of genes in dilated cardiomyopathy.Circulation. 2021; 144: 7-19
- Low mutation rate in the TTN gene in paediatric patients with dilated cardiomyopathy – a pilot study.Sci Rep. 2019; 9: 16409
- The giant protein Titin’s role in cardiomyopathy: genetic, transcriptional, and post-translational modifications of TTN and their contribution to cardiac disease.Front Physiol. 2019; 10: 1436
- Truncations of Titin causing dilated cardiomyopathy.N Engl J Med. 2012; 366: 619-628
- Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy.Circ Heart Fail. 2018; 11e005220
- Truncating Titin mutations are associated with a mild and treatable form of dilated cardiomyopathy.Eur J Heart Fail. 2017; 19: 512-521
- The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy.Circulation. 2013; 128: 1623-1633
- Right ventricular dysfunction in patients with idiopathic dilated cardiomyopathy: prognostic value and predictive factors.Arch Cardiovasc Dis. 2016; 109: 231-241
- Phenotype and clinical outcomes of Titin cardiomyopathy.J Am Coll Cardiol. 2017; 70: 2264-2274
- Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of Titin truncations in health and disease.Sci Transl Med. 2015; 7 (:270ra276-6)
- Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy.Can J Cardiol. 2021; 37: 1743-1750
- Genetic variation in Titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes.Circulation. 2011; 124: 876-885
- Recovery of cardiac function in cardiomyopathy caused by Titin truncation.JAMA Cardiol. 2016; 1: 234-235
- Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias.Eur Heart J. 2018; 39: 864-873
- Genetic determinants and genotype-phenotype correlations in Vietnamese patients with dilated cardiomyopathy.Circ J. 2021; 85: 1469-1478
Article info
Publication history
Published online: June 30, 2021
Accepted:
June 28,
2021
Received:
June 20,
2021
Footnotes
See article by Manca et al.,pages 1743–1750 of this issue.
See page 1701 for disclosure information.
Identification
Copyright
© 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Prevalence and Evolution of Right Ventricular Dysfunction Among Different Genetic Backgrounds in Dilated CardiomyopathyCanadian Journal of CardiologyVol. 37Issue 11
